Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours

IF 26.8 1区 医学 Q1 ENGINEERING, BIOMEDICAL Nature Biomedical Engineering Pub Date : 2024-07-18 DOI:10.1038/s41551-024-01239-x
Qunfeng Fu, Shuren Zhang, Siyong Shen, Zhi Gu, Junyi Chen, Dongfan Song, Pengwei Sun, Chunhong Wang, Zhibin Guo, Yunlong Xiao, Yi Qin Gao, Zijian Guo, Zhibo Liu
{"title":"Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours","authors":"Qunfeng Fu, Shuren Zhang, Siyong Shen, Zhi Gu, Junyi Chen, Dongfan Song, Pengwei Sun, Chunhong Wang, Zhibin Guo, Yunlong Xiao, Yi Qin Gao, Zijian Guo, Zhibo Liu","doi":"10.1038/s41551-024-01239-x","DOIUrl":null,"url":null,"abstract":"Pt(II) drugs are a widely used chemotherapeutic, yet their side effects can be severe. Here we show that the radiation-induced reduction of Pt(IV) complexes to cytotoxic Pt(II) drugs is rapid, efficient and applicable in water, that it is mediated by hydrated electrons from water radiolysis and that the X-ray-induced release of Pt(II) drugs from an oxaliplatin prodrug in tumours inhibits their growth, as we show with nearly complete tumour regression in mice with subcutaneous human tumour xenografts. The combination of low-dose radiotherapy with a Pt(IV)-based antibody–trastuzumab conjugate led to the tumour-selective release of the chemotherapeutic in mice and to substantial therapeutic benefits. The radiation-induced local reduction of platinum prodrugs in the reductive tumour microenvironment may expand the utility of radiotherapy. Platinum-based chemotherapeutics can be locally released in tumours by leveraging the radiation-induced reduction of platinum prodrugs.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"8 11","pages":"1425-1435"},"PeriodicalIF":26.8000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Biomedical Engineering","FirstCategoryId":"5","ListUrlMain":"https://www.nature.com/articles/s41551-024-01239-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Pt(II) drugs are a widely used chemotherapeutic, yet their side effects can be severe. Here we show that the radiation-induced reduction of Pt(IV) complexes to cytotoxic Pt(II) drugs is rapid, efficient and applicable in water, that it is mediated by hydrated electrons from water radiolysis and that the X-ray-induced release of Pt(II) drugs from an oxaliplatin prodrug in tumours inhibits their growth, as we show with nearly complete tumour regression in mice with subcutaneous human tumour xenografts. The combination of low-dose radiotherapy with a Pt(IV)-based antibody–trastuzumab conjugate led to the tumour-selective release of the chemotherapeutic in mice and to substantial therapeutic benefits. The radiation-induced local reduction of platinum prodrugs in the reductive tumour microenvironment may expand the utility of radiotherapy. Platinum-based chemotherapeutics can be locally released in tumours by leveraging the radiation-induced reduction of platinum prodrugs.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
放疗引发的肿瘤中铂类化疗原药的减少。
铂(II)药物是一种广泛使用的化疗药物,但其副作用也很严重。在这里,我们展示了辐射诱导的铂(IV)复合物还原成细胞毒性铂(II)药物的过程是快速、高效且适用于水的,它是由水辐射分解产生的水合电子介导的,X射线诱导的铂(II)药物从肿瘤中的奥沙利铂原药中释放出来,抑制了肿瘤的生长,正如我们在皮下人类肿瘤异种移植物小鼠身上所展示的那样,肿瘤几乎完全消退。低剂量放疗与基于铂(IV)的抗体-曲妥珠单抗共轭物相结合,可在小鼠体内实现肿瘤选择性释放化疗药物,并带来显著的治疗效果。铂原药在还原性肿瘤微环境中的辐射诱导局部减少可能会扩大放疗的效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nature Biomedical Engineering
Nature Biomedical Engineering Medicine-Medicine (miscellaneous)
CiteScore
45.30
自引率
1.10%
发文量
138
期刊介绍: Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.
期刊最新文献
Advancing breast cancer risk stratification using multimodal AI FAS-less allogeneic CAR T cells Concurrently depleting regulatory T cells and activating cytotoxic T cells in tumours Acoustic-pressure-driven ultrasonic activation of the mechanosensitive receptor RET and of cell proliferation in colonic tissue The analgesic potential of heavy water
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1